Rare Disease Diagnostics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 3.4 billion
Estimated Base Value
2035 Forecast
US$ 15.7 billion
Projected Market Value
CAGR 2026–2035
16.5%
Compound Annual Growth
Largest Segment
Genetic Testing
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
Largest market
Key Players
Centogene
Emerging Players
Diploid, Fabric Genomics
Rare Disease Diagnostics Market Overview
The Rare Disease Diagnostics Market provides advanced medical devices and precision medicine technologies for identifying, characterizing, and monitoring diseases that affect a small percentage of the population. This market utilizes genomic, proteomic, and imaging techniques, including next-generation sequencing and mass spectrometry, to deliver early, accurate, and personalized diagnoses. It focuses on tailoring diagnostic approaches to individual patient genetic profiles, enabling timely intervention and targeted therapeutic strategies. The primary users of these diagnostics include hospitals, diagnostic laboratories, and research institutions seeking to improve diagnostic accuracy and reduce the diagnostic odyssey for patients with rare genetic or metabolic disorders.
The market is estimated at $3.4 Bn in 2025 and is forecast to reach $15.7 Bn in 2035, growing at a CAGR of 16.5% from 2025 to 2035. Demand is driven by the high prevalence of undiagnosed rare diseases and continuous technological advancements in genomics and bioinformatics. However, the high cost of advanced diagnostic tests and limited awareness among some healthcare professionals present challenges to widespread adoption and timely diagnosis. Government funding and supportive policies for research and development also influence market expansion.
The market is segmented by Type (Genetic Testing, Biochemical Testing, Immunodiagnostics, Cytogenetic Testing, Pathology & Histology, Medical Imaging), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Mass Spectrometry, Immunoassay Techniques, Fluorescence in Situ Hybridization, Chromatography, Optical & Electron Microscopy), Application (Early Diagnosis & Screening, Confirmatory Diagnosis, Prognosis & Disease Monitoring, Therapeutic Monitoring & Pharmacogenomics, Pre-Symptomatic & Predictive Testing), End-User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Specialty Clinics, Physician Offices), Sample Type (Blood Samples, Urine Samples, Saliva Samples, Tissue Biopsy Samples, Cerebrospinal Fluid Samples, Amniotic Fluid & Chorionic Villus Samples, Buccal Swabs), and Product (Diagnostic Kits & Assays, Instruments & Analyzers, Reagents & Consumables, Bioinformatics & Data Analysis Software, Diagnostic Services). Geographically, the market is served across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include Centogene, GeneDx, Congenica, Eurofins Scientific, Revvity, Qiagen, Myriad Genetics, Fulgent Genetics, SOPHiA GENETICS, PacBio, Oxford Nanopore Technologies, and Bionano Genomics. The full report provides a comprehensive analysis of these segments and regional markets.
Market Definition & Overview
The Rare Disease Diagnostics Market encompasses advanced medical devices and precision medicine technologies utilized for the identification, characterization, and monitoring of diseases affecting a small percentage of the population. This market leverages cutting-edge genomic, proteomic, and imaging techniques, including next-generation sequencing, mass spectrometry, and advanced molecular diagnostics, to provide early, accurate, and personalized diagnoses. It focuses on tailoring diagnostic approaches to individual patient genetic profiles, enabling timely intervention and targeted therapeutic strategies. The market addresses the critical need for improved diagnostic accuracy and reduced diagnostic odyssey for patients with rare and often complex genetic or metabolic disorders.
Scope
- Global market analysis spanning major regions and countries.
- Market segmentation by diagnostic technology, disease area, and end-user.
- Forecast period covering 2025 to 2035.
Inclusions
- Next-generation sequencing (NGS) panels and services for rare diseases.
- Whole exome sequencing (WES) and whole genome sequencing (WGS) technologies.
- Molecular diagnostic assays specifically for rare genetic conditions.
- Mass spectrometry-based diagnostics for rare metabolic disorders.
- Advanced imaging techniques used for diagnosing specific rare structural diseases.
- Laboratory services and test kits dedicated to rare disease diagnosis.
Exclusions
- Therapeutic drugs for rare diseases (orphan drugs).
- General medical devices not specialized for rare disease diagnosis.
- Diagnostics for common, non-rare diseases like diabetes or cardiovascular conditions.
- Non-diagnostic medical devices used for symptomatic management of rare diseases.
Market Size Forecast
Executive Summary
• The Rare Disease Diagnostics market is valued at $3.4 Bn in 2025 and is forecast to reach $15.7 Bn by 2035, reflecting a robust CAGR of 16.5% as demand accelerates across every major segment and region over the ten-year outlook.
• Genetic Testing leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Advancements in next-generation sequencing and AI integration are profoundly reshaping diagnostic capabilities, driving earlier and more precise rare disease identification globally, demanding agile regulatory adaptation.
• Strategic consolidation among specialized diagnostic firms and larger life science entities intensifies competitive pressures, fueled by investment in niche technology platforms across major developed and emerging markets.
• Regional disparities in healthcare infrastructure and reimbursement policies significantly impact rare disease diagnostic adoption, necessitating tailored market entry and resilient supply chain optimization for equitable access.
• The future market trajectory hinges on successful biomarker discovery and companion diagnostics development, unlocking personalized therapeutic pathways and expanding diagnostic reach for underserved populations globally.
• Emerging players leveraging decentralized testing models and point-of-care innovations disrupt traditional diagnostic workflows, attracting significant venture capital and redefining competitive landscapes across key segments.
• Harmonization of international regulatory frameworks remains a critical enabler for cross-border diagnostic test approval and broader supply chain efficiency, directly influencing market penetration across diverse rare disease categories.
Key Market Takeaways
Critical findings and data points from this market research study.
Market Valuation
The Rare Disease Diagnostics Market was valued at $3.4 billion in the base year.
Impressive Growth Rate
The market is projected to expand at a Compound Annual Growth Rate (CAGR) of 16.5% over the forecast period.
Significant Future Expansion
By the forecast year, the Rare Disease Diagnostics Market is expected to reach a substantial valuation of $15.7 billion.
Robust Market Trajectory
This indicates a significant increase from its $3.4 billion base year valuation to $15.7 billion by the forecast year, driven by diagnostic advancements.
NGS Dominance
Next-Generation Sequencing (NGS) technology is anticipated to remain a leading segment, driving precision and efficiency in rare disease diagnosis.
Personalized Medicine Integration
A notable trend is the increasing adoption of personalized medicine approaches, enhancing the precision and effectiveness of rare disease diagnostics.
Market Dynamics
Market Trends
- Next-generation sequencing adoption is rapidly increasing for rare disease diagnosis.
- Artificial intelligence accelerates rare disease data analysis and interpretation.
- Emphasis on early and presymptomatic diagnosis improves patient outcomes.
- Non-invasive liquid biopsy methods are gaining prominence in diagnostics.
Growth Drivers
- High prevalence of undiagnosed rare diseases fuels diagnostic demand.
- Technological advancements in genomics and bioinformatics drive innovation.
- Increasing awareness among healthcare professionals improves early detection.
- Government funding and supportive policies boost research and development.
Restraints
- High cost of advanced diagnostic tests limits widespread adoption.
- Limited awareness among healthcare professionals delays diagnosis.
- Fragmented patient data poses challenges for research and development.
- Complex regulatory pathways create barriers for market entry.
Opportunities
- Integration of multi-omics data offers comprehensive diagnostic solutions.
- Developing novel biomarkers expands diagnostic reach for rare conditions.
- Targeted therapy companion diagnostics present significant growth potential.
- Telemedicine and digital health platforms enable wider diagnostic access.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Genetic TestingBiochemical TestingImmunodiagnosticsCytogenetic TestingPathology & HistologyMedical Imaging |
| By Technology | Next-Generation SequencingPolymerase Chain ReactionMicroarray TechnologyMass SpectrometryImmunoassay TechniquesFluorescence in Situ HybridizationChromatographyOptical & Electron Microscopy |
| By Application | Early Diagnosis & ScreeningConfirmatory DiagnosisPrognosis & Disease MonitoringTherapeutic Monitoring & PharmacogenomicsPre-Symptomatic & Predictive Testing |
| By End-User | Hospitals & ClinicsDiagnostic LaboratoriesAcademic & Research InstitutionsPharmaceutical & Biotechnology CompaniesSpecialty ClinicsPhysician Offices |
| By Sample Type | Blood SamplesUrine SamplesSaliva SamplesTissue Biopsy SamplesCerebrospinal Fluid SamplesAmniotic Fluid & Chorionic Villus SamplesBuccal Swabs |
| By Product | Diagnostic Kits & AssaysInstruments & AnalyzersReagents & ConsumablesBioinformatics & Data Analysis SoftwareDiagnostic Services |
Regional Analysis
- North America dominates the rare disease diagnostics market, driven by its sophisticated healthcare infrastructure and substantial R&D investments. High adoption of advanced genomic technologies, coupled with strong government funding for rare disease research and increased patient awareness, underpins its leadership.
- The Asia-Pacific region is projected to be the fastest-growing market, primarily due to improving healthcare infrastructure, rising disposable incomes, and increasing awareness of rare diseases. Expanding access to advanced diagnostic technologies and supportive government policies are also fueling this rapid growth.
- Europe exhibits a significant trend towards integrating Artificial Intelligence and Machine Learning into rare disease diagnostics. This enhances diagnostic accuracy and expedites patient identification, often supported by cross-border data sharing initiatives. Increased focus on personalized medicine and early genetic screening also drives innovation in the region.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Dominant due to advanced healthcare infrastructure, high R&D investment, and strong patient advocacy groups.
- Early adoption of precision medicine technologies drives market leadership.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A growing market influenced by increasing healthcare access, rising awareness of rare diseases, and investment in genetic testing infrastructure.
- However, disparities in healthcare access and funding remain challenges.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Significant market player driven by robust research initiatives, government funding for rare diseases, and established diagnostic networks.
- Increasing awareness and access to advanced genetic testing contribute to steady growth.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiencing rapid growth fueled by rising healthcare expenditure, increasing patient population, and improving diagnostic capabilities, especially in countries like China and India.
- Government initiatives to improve rare disease identification are also key drivers.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Developing market with potential driven by increasing government focus on healthcare, rising incidence of genetic disorders in some populations, and expanding medical tourism for specialized treatments.
- Infrastructure development is key to future expansion.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads in rare disease diagnostics due to extensive R&D investments, advanced healthcare infrastructure, and a high adoption rate of precision medicine technologies. Its robust regulatory framework and strong genomic research further drive market growth. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | Brazil represents the largest market in South America for rare disease diagnostics, driven by improving healthcare access and increasing awareness of genetic disorders. Government and private initiatives are boosting the adoption of advanced diagnostic tools. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany holds a leading position in Europe with its robust healthcare system, high R&D spending, and early adoption of advanced medical technologies. Strong genomic research and a favorable reimbursement landscape contribute significantly to the market. |
| 4 | China | US$ XX.X Mn | XX.X% | China is a rapidly growing market for rare disease diagnostics, driven by its vast population, increasing healthcare expenditure, and significant government investment in genomics. The expansion of diagnostic infrastructure and rising awareness are key growth factors. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Saudi Arabia is a key market in the region due to substantial government investment in healthcare infrastructure and advanced medical technologies. Increasing awareness of genetic disorders and rising demand for specialized diagnostics drive its growth. |
Countries Covered (27)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Italy, Netherlands, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Singapore, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Centogene | XX.X% | Leverage a comprehensive rare disease data repository and multi-omics approach to offer precise diagnostic solutions and accelerate drug discovery. | — | — | CenataCentoMetabolicCentoXome+1 |
| 2 | GeneDx | XX.X% | Provide advanced genomic testing services with a focus on comprehensive diagnostic solutions for rare and complex genetic disorders. | — | — | Whole Exome SequencingWhole Genome SequencingPanel Testing+1 |
| 3 | Congenica | XX.X% | Enable rapid and accurate diagnosis of rare genetic diseases through an AI-powered genomic analysis platform. | — | — | Congenica Clinical Decision Support PlatformCongenica Research PlatformCongenica Lab Management System |
| 4 | Eurofins Scientific | XX.X% | Offer a vast array of analytical testing services globally, leveraging broad laboratory network and diverse expertise to serve various industries including healthcare. | — | — | Clinical Genetic TestingNIPTOncology Testing+1 |
| 5 | Revvity | XX.X% | Provide innovative solutions across diagnostics, life sciences, and applied markets, focusing on early detection and precision medicine. | — | — | Newborn Screening SolutionsMulti-omics PlatformsDiagnostic Reagents+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Centogene, GeneDx, Congenica, Eurofins Scientific, Revvity, Qiagen, Myriad Genetics, Fulgent Genetics, SOPHiA GENETICS, PacBio, Oxford Nanopore Technologies, Bionano Genomics, Natera, Twist Bioscience, bioMérieux, ARUP Laboratories, Bio-Rad Laboratories, Veracyte, Personalis, Exagen
The global Rare Disease Diagnostics market features a competitive landscape led by Centogene, GeneDx, Congenica, Eurofins Scientific, Revvity, and Qiagen, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Centogene
GeneDx
Congenica
Eurofins Scientific
Revvity
Qiagen
Myriad Genetics
Fulgent Genetics
SOPHiA GENETICS
PacBio
Oxford Nanopore Technologies
Bionano Genomics
Natera
Twist Bioscience
bioMérieux
ARUP Laboratories
Bio-Rad Laboratories
Veracyte
Personalis
Exagen
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
GeneDx Unveils Expansive Whole Genome Sequencing Panel for Pediatric Rare Diseases
GeneDx announced the launch of a new whole-genome sequencing (WGS) panel specifically designed for rapid and comprehensive diagnosis of rare genetic conditions in pediatric patients, significantly shortening the diagnostic odyssey. This advanced panel offers enhanced coverage and improved variant detection across thousands of rare disease genes.
Quest Diagnostics Acquires AI-Powered Rare Disease Diagnostics Startup Aethos Bio
Quest Diagnostics has acquired Aethos Bio, an emerging leader in artificial intelligence and machine learning applications for rare disease diagnostics. This strategic acquisition is set to integrate Aethos Bio's advanced computational capabilities into Quest's extensive genetic testing portfolio, enhancing diagnostic accuracy and speed.
Illumina and Vertex Pharmaceuticals Announce Collaboration for Rare Genetic Disease Companion Diagnostics
Illumina and Vertex Pharmaceuticals have forged a strategic partnership to develop companion diagnostics (CDx) for Vertex's pipeline of rare genetic disease therapies. This collaboration aims to identify specific patient populations most likely to benefit from targeted treatments, accelerating access to precision medicine.
CureGenDx Secures US$ XX.X Series C to Advance Non-Invasive Rare Disease Diagnostics
CureGenDx, a pioneer in non-invasive liquid biopsy for rare genetic disorders, successfully closed a US$ XX.X Series C funding round led by major life science investors. The capital will fuel the expansion of its platform for earlier and less invasive detection of rare diseases, particularly in prenatal and neonatal settings.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $3.4 Bn |
| Market Size (Forecast) | $15.7 Bn |
| CAGR | 16.5% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 27 Countries |
| Segments Covered | 6 Segments, 37 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Rare Disease Diagnostics Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The Rare Disease Diagnostics market is estimated at $3.4 Bn in 2025. It is forecast to reach $15.7 Bn by 2035, reflecting significant growth in the sector over the next decade. These figures indicate the total market value.
The Rare Disease Diagnostics market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 16.5% from 2025 to 2035. This growth rate highlights the expanding adoption of advanced diagnostic technologies and increasing demand for early detection of rare conditions.
The market is segmented by Type (e.g., Genetic Testing), Technology (e.g., Next-Generation Sequencing), Application (e.g., Early Diagnosis & Screening), End-User (e.g., Hospitals & Clinics), Sample Type (e.g., Blood Samples), and Product (e.g., Diagnostic Kits & Assays). These categories cover the various aspects of rare disease diagnosis.
Leading companies in this market include Centogene, GeneDx, Congenica, Eurofins Scientific, Revvity, Qiagen, Myriad Genetics, Fulgent Genetics, SOPHiA GENETICS, PacBio, Oxford Nanopore Technologies, and Bionano Genomics. These companies contribute to the development and provision of diagnostic solutions.
The Rare Disease Diagnostics market report covers global market analysis across major regions and countries. It includes market segmentation by diagnostic technology, disease area, and end-user. The forecast period spans from 2025 to 2035, offering insights into market trends and future projections.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
AI Kidney Disease Diagnostics Market
$214.0 Mn in 2025 · 18.8% CAGR
Infectious Disease Diagnostics Market
$38.5 Bn in 2025 · 6.5% CAGR
Inflammatory Disease Diagnostics Market
$5.8 Bn in 2025 · 6.9% CAGR
Advanced Molecular Diagnostics Market
$14.6 Bn in 2025 · 16.2% CAGR
AI Diagnostics Market
$2.1 Bn in 2025 · 16.3% CAGR
AI Genomic Diagnostics Market
$800.1 Mn in 2025 · 24.0% CAGR
AI Neurology Diagnostics Market
$731.0 Mn in 2025 · 18.5% CAGR
AI Precision Diagnostics Engine Market
$448.0 Mn in 2025 · 21.7% CAGR